Media Articles Related to Carac (Fluorouracil Topical)
Source: MedicineNet Atopic Dermatitis Specialty [2012.06.04]
Title: Keratosis Pilaris
Category: Diseases and Conditions
Created: 8/4/2008 12:00:00 AM
Last Editorial Review: 6/4/2012 12:00:00 AM
Published Studies Related to Carac (Fluorouracil Topical)
Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in
combination with salicylic acid treating actinic keratoses. 
practicability... CONCLUSIONS: Topical 0.5% 5-FU/SA demonstrated superior sustained clinical
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance
enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line
therapy for metastatic colorectal cancer. 
maintenance therapy for metastatic colorectal cancer (MCRC)... CONCLUSIONS: Enzastaurin combined with bevacizumab-based therapy is tolerable,
Comparison of the efficacy of intralesional triamcinolone acetonide and
5-fluorouracil tattooing for the treatment of keloids. 
for treatment of keloids... CONCLUSION: 5-FU tattooing was more effective than intralesional TAC for the
Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion. [2011.11.09]
BACKGROUND: The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT). This study evaluated the efficacy of combined 5-fluorouracil and pegylated interferon (PEG-IFN) alpha-2b in patients with advanced HCC... CONCLUSIONS: Although a prospective randomized controlled trial using a larger population of patients with advanced HCC is needed to evaluate combination therapy with 5-fluorouracil and PEG-IFNalpha-2b, this new combination therapy may be useful for patients with advanced HCC. Cancer 2011;. (c) 2011 American Cancer Society. Copyright (c) 2011 American Cancer Society.
Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. [2011.11]
BACKGROUND: Actinic keratoses (AKs) arise after chronic sun exposure. Because long-term ultraviolet (UV) damage may induce proliferation of atypical keratinocytes, treatment of AKs is recommended. OBJECTIVES: To compare 5-fluorouracil 0.5%/salicylic acid 10.0% [low-dose 5-FU/SA (Actikerall(R))] with diclofenac 3% in hyaluronic acid (diclofenac HA) and vehicle for the treatment of AKs... CONCLUSIONS: Topical low-dose 5-FU/SA demonstrated higher histological and clinical clearance rates vs. diclofenac HA or vehicle. Low-dose 5-FU/SA is an effective lesion-directed treatment for AKs. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists.
Clinical Trials Related to Carac (Fluorouracil Topical)
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors [Active, not recruiting]
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with
advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor
activity, and how the study drug behaves within the body when given with 5-Fluorouracil
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma [Active, not recruiting]
This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM)
combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV).
This study will evaluate the safety and tolerability of the combination of these drugs when
they are used in the treatment of metastatic colorectal cancer.
This is a pilot clinical trial which will be studying the reactions of the patient's body and
tumor to the experimental treatment described above. The purpose of this study is to find
out what kind of side effects this experimental treatment causes and see how often these side
A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women [Completed]
To determine the efficacy and safety of intravaginal fluorouracil administered as prophylaxis
in HIV-infected women who have received standard ablative therapy (surgery) for high-grade
cervical dysplasia (pre-cancer of the cervix; cervical intraepithelial neoplasia). To
correlate time to recurrence of cervical dysplasia with T-cell function.
Women with HIV infection are at greater risk for cervical dysplasia. Because of the
likelihood that untreated or recurrent cervical dysplasia may progress to invasive cancer,
there is an urgent need to develop appropriate therapies.
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck [Completed]
To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU)
in patients with advanced inoperable or metastatic head and neck cancer and to investigate
the safety profile of this regimen in the above indication and consider other criteria of
efficacy (clinical benefit, survival)
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors [Terminated]
The main purpose of this study is to determine if XL119 is more effective than the
combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of
subjects with advanced biliary tumors.